232 related articles for article (PubMed ID: 38318826)
1. Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update.
Mudgal R; Singh S
Curr Hypertens Rev; 2024; 20(1):10-22. PubMed ID: 38318826
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction.
Pinheiro LC; Oliveira-Paula GH; Portella RL; Guimarães DA; de Angelis CD; Tanus-Santos JE
Redox Biol; 2016 Oct; 9():134-143. PubMed ID: 27521759
[TBL] [Abstract][Full Text] [Related]
3. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
4. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Battelli MG; Polito L; Bolognesi A
Atherosclerosis; 2014 Dec; 237(2):562-7. PubMed ID: 25463089
[TBL] [Abstract][Full Text] [Related]
5. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
Kelley EE
Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
[TBL] [Abstract][Full Text] [Related]
6. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidoreductase in cancer: more than a differentiation marker.
Battelli MG; Polito L; Bortolotti M; Bolognesi A
Cancer Med; 2016 Mar; 5(3):546-57. PubMed ID: 26687331
[TBL] [Abstract][Full Text] [Related]
8. A new paradigm for XOR-catalyzed reactive species generation in the endothelium.
Kelley EE
Pharmacol Rep; 2015 Aug; 67(4):669-74. PubMed ID: 26321266
[TBL] [Abstract][Full Text] [Related]
9. The double faced role of xanthine oxidoreductase in cancer.
Chen MM; Meng LH
Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
[TBL] [Abstract][Full Text] [Related]
10. Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes.
Washio K; Kusunoki Y; Tsunoda T; Osugi K; Ohigashi M; Murase T; Nakamura T; Matsuo T; Konishi K; Katsuno T; Namba M; Koyama H
Acta Diabetol; 2020 Jan; 57(1):31-39. PubMed ID: 31093763
[TBL] [Abstract][Full Text] [Related]
11. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.
Berry CE; Hare JM
J Physiol; 2004 Mar; 555(Pt 3):589-606. PubMed ID: 14694147
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
[TBL] [Abstract][Full Text] [Related]
13. Xanthine oxidoreductase: One enzyme for multiple physiological tasks.
Bortolotti M; Polito L; Battelli MG; Bolognesi A
Redox Biol; 2021 May; 41():101882. PubMed ID: 33578127
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
15. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme.
Battelli MG; Bolognesi A; Polito L
Biochim Biophys Acta; 2014 Sep; 1842(9):1502-17. PubMed ID: 24882753
[TBL] [Abstract][Full Text] [Related]
17. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
18. Tempol improves xanthine oxidoreductase-mediated vascular responses to nitrite in experimental renovascular hypertension.
Oliveira-Paula GH; Pinheiro LC; Guimaraes DA; Tella SO; Blanco AL; Angelis CD; Schechter AN; Tanus-Santos JE
Redox Biol; 2016 Aug; 8():398-406. PubMed ID: 27078869
[TBL] [Abstract][Full Text] [Related]
19. Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis.
Peleli M; Zollbrecht C; Montenegro MF; Hezel M; Zhong J; Persson EG; Holmdahl R; Weitzberg E; Lundberg JO; Carlström M
Free Radic Biol Med; 2016 Oct; 99():472-484. PubMed ID: 27609225
[TBL] [Abstract][Full Text] [Related]
20. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Okuyama T; Shirakawa J; Nakamura T; Murase T; Miyashita D; Inoue R; Kyohara M; Togashi Y; Terauchi Y
Sci Rep; 2021 Feb; 11(1):3768. PubMed ID: 33580173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
